TY - JOUR
T1 - Alzheimer's disease-related dementias summit 2016
T2 - National research priorities
AU - Corriveau, Roderick A.
AU - Koroshetz, Walter J.
AU - Gladman, Jordan T.
AU - Jeon, Sophia
AU - Babcock, Debra
AU - Bennett, David A.
AU - Carmichael, S. Thomas
AU - Dickinson, Susan L.J.
AU - Dickson, Dennis W.
AU - Emr, Marian
AU - Fillit, Howard
AU - Greenberg, Steven M.
AU - Hutton, Michael L.
AU - Knopman, David S.
AU - Manly, Jennifer J.
AU - Marder, Karen S.
AU - Moy, Claudia S.
AU - Phelps, Creighton H.
AU - Scott, Paul A.
AU - Seeley, William W.
AU - Sieber, Beth Anne
AU - Silverberg, Nina B.
AU - Sutherland, Margaret L.
AU - Taylor, Angela
AU - Torborg, Christine L.
AU - Waddy, Salina P.
AU - Gubitz, Amelie K.
AU - Holtzman, David M.
N1 - Funding Information:
From the National Institute of Neurological Disorders and Stroke (R.A.C., W.J.K., J.T.G., S.J., D.B., M.E., C.S.M., P.A.S., B.-A.S., M.L.S., C.L.T., A.K.G.), Bethesda, MD; Rush Alzheimer’s Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.C.), David Geffen School of Medicine, University of California, Los Angeles; The Association for Frontotemporal Degeneration (S.L.-J.D.), Radnor, PA; Department of Neuroscience (D.W.D.), Mayo Clinic, Jacksonville, FL; The Alzheimer’s Drug Discovery Foundation (H.F.); Icahn School of Medicine at Mount Sinai (H.F.), New York, NY; Department of Neurology (S.M.G.), Massachusetts General Hospital, Harvard Medical School, Boston; Eli Lilly and Company (M.L.H.), Lilly Research Centre, Erl Wood Manor, Windlesham, UK; Department of Neurology (D.S.K.), Mayo Clinic Rochester, MN; Taub Institute for Research on Alzheimer’s Disease and the Aging Brain (J.J.M., K.S.M.) and College of Physicians and Surgeons (K.S.M.), Columbia University, New York, NY; National Institute on Aging (C.H.P., N.B.S.), Bethesda, MD; Memory and Aging Center, Department of Neurology (W.W.S.), and Department of Pathology (W.W.S.), University of California San Francisco; Lewy Body Dementia Association (A.T.), Lilburn, GA; National Institute of Diabetes and Digestive and Kidney Diseases (S.P.W.), Bethesda, MD; and Knight Alzheimer’s Disease Research Center (D.M.H.), Hope Center for Neurological Disorders (D.M.H.), and Department of Neurology (D.M.H.), Washington University in St. Louis, MO. Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Funding Information:
The conference was supported by NINDS, organized in collaboration with the National Institute on Aging, with assistance from the Foundation for the NIH and additional support from the NIH Office of Disease Prevention, the Alzheimer’s Association, Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD), the American Heart Association/American Stroke Association, the Association for Frontotemporal Degeneration, Axovant Sciences, the BrightFocus Foundation, and the LEAD Coalition (Leaders Engaged on Alzheimer’s Disease Coalition).
Publisher Copyright:
© 2017 American Academy of Neurology.
PY - 2017/12
Y1 - 2017/12
N2 - Goal 1 of the National Plan to Address Alzheimer's Disease is to prevent and effectively treat Alzheimer disease and Alzheimer disease-related dementias by 2025. To help inform the research agenda toward achieving this goal, the NIH hosts periodic summits that set and refine relevant research priorities for the subsequent 5 to 10 years. This proceedings article summarizes the 2016 Alzheimer's Disease-Related Dementias Summit, including discussion of scientific progress, challenges, and opportunities in major areas of dementia research, including mixedetiology dementias, Lewy body dementia, frontotemporal degeneration, vascular contributions to cognitive impairment and dementia, dementia disparities, and dementia nomenclature.
AB - Goal 1 of the National Plan to Address Alzheimer's Disease is to prevent and effectively treat Alzheimer disease and Alzheimer disease-related dementias by 2025. To help inform the research agenda toward achieving this goal, the NIH hosts periodic summits that set and refine relevant research priorities for the subsequent 5 to 10 years. This proceedings article summarizes the 2016 Alzheimer's Disease-Related Dementias Summit, including discussion of scientific progress, challenges, and opportunities in major areas of dementia research, including mixedetiology dementias, Lewy body dementia, frontotemporal degeneration, vascular contributions to cognitive impairment and dementia, dementia disparities, and dementia nomenclature.
UR - http://www.scopus.com/inward/record.url?scp=85038263087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038263087&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000004717
DO - 10.1212/WNL.0000000000004717
M3 - Review article
C2 - 29117955
AN - SCOPUS:85038263087
SN - 0028-3878
VL - 89
SP - 2381
EP - 2391
JO - Neurology
JF - Neurology
IS - 23
ER -